 Insulin, Long-Acting
"Insulin, Long-Acting" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Insulin formulations that contain substances that retard absorption thus extending the time period of action.
| Descriptor ID |
D049528
|
| MeSH Number(s) |
D06.472.699.587.200.300 D12.644.548.586.200.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Insulin, Long-Acting".
Below are MeSH descriptors whose meaning is more specific than "Insulin, Long-Acting".
This graph shows the total number of publications written about "Insulin, Long-Acting" by people in this website by year, and whether "Insulin, Long-Acting" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 4 | 4 | | 2005 | 0 | 3 | 3 | | 2006 | 0 | 1 | 1 | | 2008 | 0 | 3 | 3 | | 2009 | 0 | 4 | 4 | | 2010 | 0 | 4 | 4 | | 2011 | 2 | 1 | 3 | | 2012 | 2 | 0 | 2 | | 2013 | 2 | 2 | 4 | | 2017 | 3 | 0 | 3 | | 2019 | 1 | 0 | 1 | | 2020 | 2 | 0 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Insulin, Long-Acting" by people in Profiles.
-
Zhang H, Barner JC, Moczygemba LR, Rascati KL. Assessment of basal insulin adherence using 2 methodologies among Texas Medicaid enrollees with type 2 diabetes. J Manag Care Spec Pharm. 2020 Nov; 26(11):1434-1444.
-
Hirsch IB, Draznin B. Transition of Patients to and from Insulin Degludec: A Clinical Challenge. J Clin Endocrinol Metab. 2020 06 01; 105(6).
-
Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Adv Ther. 2019 02; 36(2):265-277.
-
Anderson SL, Trujillo JM, Anderson JE, Tanenberg RJ. Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. Postgrad Med. 2018 Mar; 130(2):229-238.
-
Akturk HK, Shah VN. Severe Hypoglycemia in Adults With Type 1 Diabetes After Switching to Insulin Degludec. J Diabetes Sci Technol. 2018 05; 12(3):733-734.
-
Ji L, Zhang P, Zhu D, Li X, Ji J, Lu J, Guo X, Jia W, Weng J, Wu Y, Yang W, Zou D, Zhou Z, Pan C, Gao Y, Garg SK. Observational Registry of Basal Insulin Treatment (ORBIT) in patients with type 2 diabetes uncontrolled with oral antihyperglycaemic drugs: Real-life use of basal insulin in China. Diabetes Obes Metab. 2017 06; 19(6):822-830.
-
Shah VN, Moser EG, Blau A, Dhingra M, Garg SK. The future of basal insulin. Diabetes Technol Ther. 2013 Sep; 15(9):727-32.
-
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013 Nov; 30(11):1293-7.
-
Dailey GE, Gao L, Aurand L, Garg SK. Impact of diabetes duration on hypoglycaemia in patients with type 2 diabetes treated with insulin glargine or NPH insulin. Diabetes Obes Metab. 2013 Dec; 15(12):1085-92.
-
Rendell M, Akturk HK, Tella SH. Glargine safety, diabetes and cancer. Expert Opin Drug Saf. 2013 Mar; 12(2):247-63.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|